Tailwinds Drive Lilly Growth, But Headwinds Remain
This article was originally published in Scrip
Executive Summary
Eli Lilly & Co. investors were somewhat enthusiastic on Jan. 5 about the big pharma company's forecast for growth in 2016 even though Lilly's guidance for $20.2bn to $20.7bn in revenue and $3.45 to $3.55 in earnings per share (EPS) fell below Wall Street analysts' expectations, due to well-known challenges that could moderate tailwinds driving revenue and earnings gains this year.